8 June 2026 - Top Stories

AstraZeneca pulls the Zoladex 3.6 mg implant from Australia and launches a six‑month Access Program, centralising access decisions for prostate cancer therapy under a single sponsor.

Australian patients relying on the monthly Zoladex implant face continuity risk as PBS coverage ends and private prescriptions stop on 1 November 2026. In 2026, 29,680 doses were dispensed, and the 10.8 mg dose remains PBS listed for prostate cancer. The Access Program offers free access for eligible patients while regulatory and reimbursement work proceeds, forcing clinics to map alternatives and adjust care workflows to avoid treatment gaps.

Alcidion and Gold Coast Health have formalised a collaboration to advance the Miya Precision remote patient monitoring platform, creating a scalable channel for jointly developed features guided by clinicians and GC Health governance. Enhancements identified in the partnership will be implemented and then disseminated to other services using Miya Precision, accelerating diffusion of digital health tools.

Geoff Taylor's career highlights ongoing rural GP workforce pressures and the growing value of telemedicine and dermatology support tools in remote Western Australia. Digital health adoption will be critical to sustaining care where clinician access is limited, pushing health systems to invest in remote consultation capacity and training for rural clinicians.

A Lancet CKD series reframes chronic kidney disease as a treatable multisystem condition, noting up to 844 million people worldwide and about 2.7 million Australians with markers, with just 7.4% aware of their condition. The report calls for routine urine testing and simple urine–blood panels alongside blood pressure checks to detect CKD early and to improve eGFR estimates when creatinine is combined with cystatin C, widening the case for digital screening and integrated care pathways in Australia.

The Therapeutic Goods Administration clarifies when compounding medicines can be supplied under the Act and outlines penalties up to 1.65 million dollars. This raises governance costs for small clinics and for vendors supporting compounding workflows, increasing demand for compliant prescribing, inventory and workflow software in Australian pharmacies.

• AstraZeneca withdraws Zoladex 3.6 mg implant from Australia on 1 November 2026 — health services must identify alternatives and adjust procurement as PBS coverage ends.
• Alcidion and Gold Coast Health sign a formal Miya Precision collaboration — this creates a scalable path for jointly developed features and diffusion to other services.
• Rural GP workforce pressures underscore the need for telemedicine and dermatology support tools — digital health solutions become essential for sustaining care in remote Western Australia.
• Lancet CKD series urges routine urine testing and simple urine–blood panels with cystatin C — this drives demand for digital screening platforms and integrated care workflows in Australia.
• TGA compounding rules and penalties up to 1.65 million dollars — compliance costs rise for small clinics and boost demand for compliant IT and workflow software.